Your browser doesn't support javascript.
loading
Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study.
Wilbraham, Darren; Berg, Paul H; Tsai, Max; Liffick, Emily; Loo, Li Shen; Doty, Erin Gautier; Sellers, Edward.
Afiliación
  • Wilbraham D; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Berg PH; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Tsai M; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Liffick E; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Loo LS; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Doty EG; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Sellers E; DL Global Partners Inc., Toronto, Ontario, Canada.
J Clin Pharmacol ; 60(4): 495-504, 2020 04.
Article en En | MEDLINE | ID: mdl-31745991

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piperidinas / Piridinas / Benzamidas / Agonistas de Receptores de Serotonina Tipo de estudio: Clinical_trials / Etiology_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piperidinas / Piridinas / Benzamidas / Agonistas de Receptores de Serotonina Tipo de estudio: Clinical_trials / Etiology_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article